• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Biotech Veru's Treatment Could Be a Game Changer, but What About the Stock?

Let's check out the charts of this biotech name.
By BRUCE KAMICH
Dec 15, 2020 | 08:57 AM EST
Stocks quotes in this article: VERU

For his second "Executive Decision" segment of Mad Money Monday evening, Jim Cramer spoke with Dr. Mitchell Steiner, chairman, president and CEO of Veru (VERU) , a biotech leading a charge against breast and prostate cancer.

Steiner explained that Veru's goal is to change the standard of care for patients diagnosed with breast or prostate cancer. He said those with breast cancer don't want the side effects of traditional chemotherapy, which is why Veru's treatment, which received positive Phase II trial data Monday, is an oral pill that can be taken at home instead of having to receive chemotherapy.

Unlike chemo, Veru's pill eliminates the typical side effects and has the added benefits of increasing function and building bones. The company expects a Phase III study, which will include 240 patients, to be concluded in 18 to 24 months.

Veru's prostate cancer treatment has a similar profile, Steiner said, and is simply a pill that can change the standard of care for the most common form of cancer in men.

Let's play doctor and check out the charts of this patient.

In the daily Japanese candlestick chart of VERU, below, we can see that the shares declined from late January until late October -- not the picture of the next big rally. Monday's candle pattern is likely a high wave candle or a long-legged doji -- both of which can mark a price high. Prices were below the moving averages until November.

Trading volume was very light until recent days when it surged dramatically. The On-Balance-Volume (OBV) line was flat until it turned sharply higher this month. The Moving Average Convergence Divergence (MACD) oscillator turned bullish in November so there was some advance notice.

In the weekly Japanese candlestick chart of VERU, below, we get a different perspective. The daily chart shows a decline for much of 2020 but this chart shows a base pattern for 2017 and 2018 followed by a rally into early 2020. The base around $2 gives a more constructive picture. Prices are extended above the rising 40-week moving average line so a correction is likely at some point.

The OBV line and trading volume show just two weeks of "action." The MACD oscillator is suddenly bullish.

In this weekly Point and Figure chart of VERU, below, we can see that prices broke out at $10 and there is a potential $26 price target.

Bottom-line strategy: A new treatment for these two cancers is very exciting and could be a real blockbuster, but we may not know the results of the Phase III study for two years. Prices are extended (overbought) so this is more likely a time to take profits and let a correction unfold.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Drug Approvals | Investing | Technical Analysis | Biotechnology | Pharmaceuticals | Mad Money | Executive Interview

More from Investing

A REIT With Large Total Return Potential and a Generous Current Yield

Paul Price
Jul 4, 2022 9:00 AM EDT

The safe route is to buy shares, collect the generous dividends and reap the rewards when valuations revert back to normal.

Bearish Bets: 3 Stocks You Should Consider Shorting This Week

Bob Lang
Jul 3, 2022 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

Let's Shine a Light on Lucid Motors as It Slides Downhill

Brad Ginesin
Jul 2, 2022 1:00 PM EDT

LCID's market cap has been deflated, so is it now a bargain, or can it slip further?

Stop Wishing, Hoping and Praying and Take Control of Your Investing

James "Rev Shark" DePorre
Jul 2, 2022 10:00 AM EDT

The most powerful thing an investor can do is embrace the idea that they don't know what the future holds.

If You've Got Time, These Three Dividend Aristocrats Should Pay Off

Bob Ciura
Jul 2, 2022 7:30 AM EDT

There high-growth dividend stocks will be here over the long haul.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:34 AM EDT PAUL PRICE

    A $525,000 Vote of Confidence on Macerich (MAC)

  • 09:49 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Stop Wishing, Hoping, and Praying and Take Control...
  • 07:59 PM EDT PAUL PRICE

    Very Good Quarterly Numbers From Bassett Furniture (BSET)

    Bassett Furniture blew right through analysts es...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login